Lactoferrin gene knockdown leads to similar effects to iron chelation in human adipocytes

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 3, 2014, Pages 391-395

  Moreno Navarrete, José María ^a   Ortega, Francisco ^a   Moreno, Maria ^a   Serrano, Marta ^a   Ricart, Wifredo ^a   Fernández Real, José Manuel ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipocytes; Adipogenesis; Iron metabolism; Lactoferrin

Indexed keywords

BIOLOGICAL MARKER; DEFEROXAMINE; IRON; IRON CHELATING AGENT; LACTOFERRIN;

ADIPOCYTE; ADIPOGENESIS; DRUG EFFECTS; GENE SILENCING; GENETICS; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY;

ADIPOCYTES; ADIPOGENESIS; BIOMARKERS; DEFEROXAMINE; GENE KNOCKDOWN TECHNIQUES; HUMANS; INFLAMMATION; IRON; IRON CHELATING AGENTS; LACTOFERRIN;

EID: 84894587549     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12234     Document Type: Article

References (15)

1. Moreno-Navarrete JM, Serrano M, Sabater M, et al. Study of lactoferrin gene expression in human and mouse adipose tissue, human preadipocytes and mouse 3T3-L1 fibroblasts. Association with adipogenic and inflammatory markers. J Nutr Biochem. 2013; 24: 1266-75.
2. Moreno-Navarrete JM, Ortega FJ, Bassols J, et al. Association of circulating lactoferrin concentration and 2 nonsynonymous LTF gene polymorphisms with dyslipidemia in men depends on glucose-tolerance status. Clin Chem. 2008; 54: 301-9.
3. Moreno-Navarrete JM, Ortega FJ, Bassols J, et al. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. J Clin Endocrinol Metab. 2009; 94: 4036-44.
4. Moreno-Navarrete JM, Ortega F, Sabater M, et al. Proadipogenic effects of lactoferrin in human subcutaneous and visceral preadipocytes. J Nutr Biochem. 2011; 22: 1143-9.
5. Ortega FJ, Mayas D, Moreno-Navarrete JM, et al. The gene expression of the main lipogenic enzymes is downregulated in visceral adipose tissue of obese subjects. Obesity. 2010; 18: 13-20.
6. Dolinková M, Dostálová I, Lacinová Z, et al. The endocrine profile of subcutaneous and visceral adipose tissue of obese patients. Mol Cell Endocrinol. 2008; 291: 63-70.
7. Ranganathan G, Unal R, Pokrovskaya I, et al. The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: effects of obesity, insulin resistance, and TZD treatment. J Lipid Res. 2006; 47: 2444-50.
8. Paesano R, Pietropaoli M, Gessani S, et al. The influence of lactoferrin, orally administered, on systemic iron homeostasis in pregnant women suffering of iron deficiency and iron deficiency anaemia. Biochimie. 2009; 91: 44-51.
9. Ward PP, Conneely OM. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals. 2004; 17: 203-8.
10. Gabrielsen JS, Gao Y, Simcox JA, et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012; 122: 3529-40.
11. Grey A, Banovic T, Zhu Q, et al. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol Endocrinol. 2004; 18: 2268-78.
12. Ono T, Murakoshi M, Suzuki N, et al. Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets. Br J Nutr. 2010; 104: 1688-95.
13. Pilvi TK, Harala S, Korpela R, et al. Effects of high-calcium diets with different whey proteins on weight loss and weight regain in high-fat-fed C57BL/6J mice. Br J Nutr. 2009; 102: 337-41.
14. Shi J, Finckenberg P, Martonen E, et al. Metabolic effects of lactoferrin during energy restriction and weight regain in diet-induced obese mice. J Funct Foods. 2012; 4: 66-78.
15. Morishita S, Ono T, Fujisaki C, et al. Bovine lactoferrin reduces visceral fat and liver triglycerides in ICR mice. J Oleo Sci. 2013; 62: 97-103.